Myocardial fibrosis is the buildup of excess scar-like tissue in the heart muscle, and it sits at the crossroads of nearly every form of serious heart disease. Whether triggered by a heart attack, long-standing high blood pressure, diabetes, infection, or an inherited condition, the end result is similar: stiff, poorly conducting heart tissue that raises the risk of heart failure, dangerous heart rhythms, and sudden cardiac death.1PubMed Central. Detection of myocardial fibrosis: Where we stand The condition is common, often silent in its early stages, and increasingly treatable when caught in time.
How Scar Tissue Forms in the Heart
Heart muscle cells have very limited ability to regenerate in adults. When they die or come under chronic stress, the body fills the gap with collagen, the same structural protein found in tendons and skin. The cells primarily responsible for laying down that collagen are fibroblasts, which under sustained signaling transform into a more active form called myofibroblasts. These myofibroblasts produce collagen at a much higher rate than ordinary fibroblasts.2PubMed. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts The transformation is driven largely by a signaling molecule called TGF-β, which plays a central role across virtually every form of cardiac fibrosis.3PubMed Central. Mechanism of action of non-coding RNAs and traditional Chinese medicine in myocardial fibrosis: Focus on the TGF-β/Smad signaling pathway
Two broad patterns exist. Replacement fibrosis occurs when dead heart cells are swapped out for scar, as happens after a heart attack. Reactive (or interstitial) fibrosis develops between still-living heart cells in response to chronic stress such as high blood pressure or metabolic disease. Both types stiffen the heart and disrupt its electrical wiring, but they arise through somewhat different triggers and carry different implications for treatment.
Causes of Myocardial Fibrosis
Almost any condition that damages or chronically stresses the heart can promote fibrosis. The most common drivers fall into several broad categories.
Heart Attack and Ischemic Injury
After a heart attack, a wave of inflammation sweeps through the damaged area. That inflammatory phase gradually gives way to a repair phase in which fibroblasts proliferate, transform into myofibroblasts, and deposit large amounts of collagen to form a scar that holds the weakened wall together.4PubMed Central. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis The scar prevents the ventricle from rupturing, but it cannot contract the way healthy muscle does, so pumping efficiency drops.5PubMed Central. Cellular and molecular signals of cardiac wound healing after myocardial infarction In the weeks that follow, the scar matures and the surrounding tissue may also develop reactive fibrosis, further worsening heart function over time.6PubMed Central. The cardiac wound healing response to myocardial infarction
Chronic High Blood Pressure
When the heart works against elevated pressure year after year, the muscle thickens and the tissue between cells accumulates collagen. A key driver is the renin-angiotensin system, the same hormonal pathway that blood-pressure medications target. Angiotensin II, one of its main products, directly stimulates fibroblasts to make more collagen while also blocking the enzymes that break collagen down.7PubMed. Renin-angiotensin system and myocardial fibrosis in hypertension: regulation of the myocardial collagen matrix Animal studies suggest angiotensin II promotes fibrosis partly through an inflammatory cascade that operates independently of blood pressure itself, meaning that even when pressure is controlled, the fibrotic signaling can persist if angiotensin activity is not blocked.8PubMed. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis
Diabetes and Metabolic Disease
High blood sugar promotes fibrosis by a mechanism distinct from pressure overload. Excess glucose reacts with long-lived proteins such as collagen to form compounds called advanced glycation end products, or AGEs. These chemically cross-link collagen fibers, making them stiffer and harder for the body to recycle, which leads to progressive accumulation of matrix proteins in the heart.9PubMed Central. Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart AGEs also bind to receptors on cell surfaces and trigger inflammatory and pro-fibrotic signaling, amplifying the problem.10PubMed Central. The Role of Advanced Glycation End-Products in the Pathophysiology and Pharmacotherapy of Cardiovascular Disease In patients with diabetes whose heart pumping is already reduced, AGE deposits in heart tissue can be roughly three times higher than in non-diabetic patients.11PubMed. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension
Myocarditis and Inflammatory Heart Disease
Viral infections, autoimmune attacks, and other inflammatory insults can trigger fibrosis even in the absence of coronary artery disease or high blood pressure. Inflammation and fibrosis are tightly intertwined: the same immune cells recruited to fight an infection release signals that later push fibroblasts toward collagen production.12PubMed Central. From Inflammation to Fibrosis-Molecular and Cellular Mechanisms of Myocardial Tissue Remodelling and Perspectives on Differential Treatment Opportunities In viral myocarditis, for instance, activated immune cells produce substances that injure muscle fibers and promote scarring, particularly around small blood vessels and along muscle bundles.13Frontiers in Pharmacology. Mechanisms and Therapeutic Strategies of Viral Myocarditis Targeting Autophagy – Section: 2 Epidemiology, Pathogens, Pathogenesis, and Pathology of Viral Myocarditis Heart-infiltrating immune cells can also contain progenitor cells that themselves become a source of fibrosis-promoting signals in later, chronic stages of disease.14Trends in Cardiovascular Medicine. Mechanisms of Cardiac Fibrosis in Inflammatory Heart Disease
Inherited Cardiomyopathies
Genetic mutations that cause hypertrophic cardiomyopathy, dilated cardiomyopathy, and other hereditary heart muscle diseases almost always involve some degree of fibrosis as part of the remodeling process.15Trends in Cardiovascular Medicine. Current understanding of fibrosis in genetic cardiomyopathies In hypertrophic cardiomyopathy, fibrosis can begin even before the heart wall visibly thickens. A study in the New England Journal of Medicine found that people carrying the mutation but without detectable wall thickening already had blood markers of increased collagen production that were about 31% higher than in healthy controls, though visible scar on cardiac MRI only appeared in those with overt disease.16PubMed Central. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy This suggests fibrosis is not just a late consequence of these diseases but may be part of the earliest tissue changes.
Radiation and Toxic Exposures
Chest radiation therapy, commonly used for breast cancer and lymphoma, can cause fibrosis of the heart muscle as a late complication. Radiation-induced myocardial fibrosis reduces the heart’s ability to stretch and fill, potentially leading to heart failure or sudden death months to years after treatment.17PubMed Central. Radiation-induced myocardial fibrosis: Mechanisms underlying its pathogenesis and therapeutic strategies Certain chemotherapy drugs, heavy alcohol use, and other cardiotoxic exposures can also contribute.
How Fibrosis Affects Heart Function
Myocardial fibrosis does not produce a single distinctive symptom the way, say, a broken bone produces pain. Instead, it gradually undermines two core functions of the heart: relaxation and electrical conduction. The symptoms a person eventually notices depend on how much fibrosis is present and where it sits.
The first thing to suffer is usually the heart’s ability to relax and fill with blood between beats. Collagen deposits stiffen the muscle wall, slowing relaxation and reducing the suction that normally pulls blood into the ventricle.18PubMed. Cardiac fibrosis as a cause of diastolic dysfunction Research using cardiac MRI has confirmed that the degree of diffuse fibrosis tracks closely with the severity of filling problems, including in patients who have heart failure despite a normal pumping fraction, a condition known as heart failure with preserved ejection fraction.19JACC: Cardiovascular Imaging. CMR-Verified Diffuse Myocardial Fibrosis Is Associated With Diastolic Dysfunction in HFpEF The practical consequence is shortness of breath, fluid retention, and exercise intolerance, often appearing gradually enough that people attribute them to aging or deconditioning.
The second major effect is on the heart’s electrical system. Healthy heart muscle conducts electrical impulses smoothly from cell to cell. Fibrotic tissue interrupts those connections, slowing conduction, creating dead-end pathways, and setting up conditions where electrical signals can circle back on themselves in what clinicians call reentry circuits.20PubMed Central. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils When fibroblasts are electrically coupled to neighboring muscle cells, they can alter the resting electrical state of those cells, further extending the period during which a premature beat can trigger a dangerous rhythm.21Heart Rhythm. Effects of fibroblast-myocyte coupling on cardiac conduction and vulnerability to reentry: A computational study This helps explain why people with significant scarring are at elevated risk of ventricular tachycardia and sudden cardiac death, even when their overall pump function seems reasonable.
One imaging study found that evidence of scar on cardiac MRI was present in only about 13% of patients with normal filling patterns, but in 87% of those with the most severe filling abnormality.22PubMed Central. Influence of myocardial fibrosis on left ventricular diastolic function: noninvasive assessment by cardiac magnetic resonance and echo That steep gradient underscores how central fibrosis is to the progression from early stiffness to full-blown heart failure.
Detecting Fibrosis Without Surgery
Historically, the only way to confirm myocardial fibrosis was through an endomyocardial biopsy, a procedure in which a small tissue sample is taken from the inside of the heart. Biopsy remains the gold standard for certain diagnoses, especially myocarditis and transplant rejection.23EuroIntervention. Endomyocardial biopsy But it is invasive, samples only a tiny area, and carries small but real risks. The field has moved heavily toward noninvasive alternatives.
Cardiac MRI is now the workhorse for detecting fibrosis. Two complementary techniques are used. Late gadolinium enhancement, or LGE, highlights areas of replacement scar by exploiting the fact that a contrast agent lingers longer in fibrotic tissue. It is excellent for spotting discrete scars after a heart attack or in cardiomyopathy. T1 mapping and extracellular volume measurement go a step further by quantifying diffuse, interstitial fibrosis that LGE can miss. Research in patients with dilated cardiomyopathy has shown that prolonged T1 values and elevated extracellular volume can reveal early fibrosis even when no LGE is visible.24PubMed. Early detection of myocardial fibrosis in cardiomyopathy in the absence of late enhancement: role of T1 mapping and extracellular volume analysis
Echocardiography with strain imaging has also gained ground as a more accessible, less expensive screening tool. Strain imaging measures how much the heart muscle deforms during each beat and can detect subtle declines in function that suggest underlying fibrosis before conventional measures like ejection fraction show a problem.25PubMed Central. Clinical Utility of Strain Imaging in Assessment of Myocardial Fibrosis It is widely available and does not require contrast agents or specialized MRI scanners, making it practical for broader populations.
Blood biomarkers add another layer of information. Galectin-3, a protein involved in fibroblast activation, has been linked to increased risk of developing heart failure and to worse outcomes in people who already have it.26PubMed Central. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community Fragments of procollagen that spill into the blood during active collagen production (PICP, PIIINP) and collagen breakdown (CITP, MMP-1) can indicate whether fibrosis is actively advancing or stabilizing. In the CARE-HF trial, higher galectin-3 and PIIINP levels were associated with worse long-term cardiovascular outcomes in heart failure patients.27PubMed. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF trial No single blood test definitively diagnoses fibrosis, but used alongside imaging, these markers help clinicians track disease activity and treatment response.
Current Treatment Strategies
No drug is specifically approved with “anti-fibrotic” on its label for cardiac use, but several widely prescribed heart failure medications have demonstrated clear anti-fibrotic effects, and that is a big part of why they work.
Mineralocorticoid receptor antagonists, particularly spironolactone and eplerenone, stand out. In a randomized clinical trial of people at increased risk for heart failure, spironolactone reduced a blood marker of active collagen synthesis (PICP) compared to control, confirming that its benefits are not just about fluid balance.28European Heart Journal. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial In animal models of heart failure after a heart attack, spironolactone was the only drug among ACE inhibitors, beta-blockers, and the mineralocorticoid antagonist itself that significantly reduced fibrosis in the atria, an important substrate for atrial fibrillation.29European Heart Journal. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction
ACE inhibitors and angiotensin receptor blockers target the renin-angiotensin pathway described earlier and are the backbone of treatment for hypertensive heart disease. In some contexts, combining them with spironolactone appears to add further benefit. A study in a mouse model of Duchenne muscular dystrophy showed that early combined treatment with lisinopril and spironolactone preserved heart function at roughly 80% of normal and markedly reduced muscle damage, compared to a decline to about 40% of normal skeletal muscle function without treatment.30PubMed Central. Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice
Newer drug classes are adding to the toolkit. SGLT2 inhibitors like empagliflozin, originally developed for diabetes, have rapidly been adopted into heart failure care. In animal studies of heart attack, empagliflozin treatment shifted scar composition toward softer collagen types and away from the stiff, cross-linked collagen that worsens remodeling. When combined with sacubitril/valsartan, the effects on scar collagen content and overall fibrosis burden trended even lower.31PubMed Central. Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study A separate study confirmed that the combination outperformed either drug alone in reducing myocardial collagen content, oxidative stress, and inflammatory markers.32PubMed Central. Dual Empagliflozin and Sacubitril/Valsartan Therapy Improves Ex Vivo Cardiac Function in a Rat Model of Heart Failure
Exercise as an Anti-Fibrotic Intervention
Structured exercise has shown surprisingly potent effects on cardiac fibrosis in animal research, operating through some of the same molecular pathways that drug therapy targets. In mice with experimentally induced heart attacks, both aerobic and resistance training significantly reduced fibrosis, suppressed TGF-β signaling, lowered collagen production, and improved antioxidant defenses in the scarred heart.33PubMed Central. Exercise Training Alleviates Cardiac Fibrosis through Increasing Fibroblast Growth Factor 21 and Regulating TGF-β1-Smad2/3-MMP2/9 Signaling in Mice with Myocardial Infarction In diabetic rats, long-term moderate exercise reversed many of the fibrotic changes driven by metabolic disease, including suppressing key collagen-stimulating signals and restoring some of the protective factors that normally keep fibrosis in check.34PubMed Central. Long-term moderate intensity exercise alleviates myocardial fibrosis in type 2 diabetic rats via inhibitions of oxidative stress and TGF-β1/Smad pathway
Translating these animal results directly to human prescriptions is not straightforward. But the findings align with the well-established clinical observation that cardiac rehabilitation programs improve outcomes after heart attacks and in heart failure. The emerging picture is that regular physical activity may not only improve symptoms through better cardiovascular fitness but may also slow or partially reverse the fibrotic remodeling that drives disease progression. For people at risk, this is one of the few interventions that is free, widely accessible, and targets fibrosis at the molecular level.
Experimental Approaches on the Horizon
The most attention-grabbing experimental approach borrows from cancer therapy: CAR T-cells engineered to attack fibrosis-producing cells in the heart. Researchers have designed T cells that target fibroblast activation protein (FAP), a marker expressed on the activated fibroblasts responsible for excessive collagen deposition. In mouse models of both autoimmune and viral myocarditis, these FAP-targeted CAR T-cells reduced fibrosis by roughly 55 to 65% and restored the heart’s ejection fraction to above 65%.35PubMed Central. Engineered T cell therapy for the treatment of cardiac fibrosis during chronic phase of myocarditis Nanoparticle-based delivery systems are also under investigation as a way to deliver CAR T-cell therapy more precisely and reduce the risk of off-target effects.36PubMed Central. Revolutionizing cardiac fibrosis treatment: the potential of personalized CAR T-cell therapy
Bioengineering approaches are also being explored. One animal study tested an electrospun patch loaded with a recombinant form of ACE2, an enzyme that counteracts the pro-fibrotic arm of the renin-angiotensin system. Applied directly to the heart, the patch delivered sustained ACE2 activity and improved ejection fraction to about 55%, compared with roughly 28 to 29% in controls. Injecting the same enzyme without the patch produced only short-lived benefit because ACE2 breaks down quickly in the body.37npj Regenerative Medicine. Myocardial fibrosis reversion via rhACE2-electrospun fibrous patch for ventricular remodeling prevention These results are strictly preclinical, but they demonstrate that the field is moving toward strategies that go beyond slowing fibrosis and aim to actively reverse it.
Can Established Fibrosis Be Reversed?
A common assumption, even among clinicians, is that once scar is laid down in the heart it is permanent. The reality is more nuanced. Dense, mature replacement scars after large heart attacks are probably irreversible with any current technology. But the cells within fibrotic tissue are not necessarily locked into their state. A study examining heart tissue from patients with end-stage heart failure found that the myofibroblasts responsible for fibrosis showed varying degrees of activation and retained the ability to revert to a less active phenotype.38PubMed. Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure This finding is significant because it means that even in advanced disease, the cellular machinery for fibrosis is not a one-way street. Therapies that can push myofibroblasts back toward a quiescent state, or selectively eliminate them, could in principle reduce collagen burden over time.
Reactive fibrosis, the diffuse type driven by chronic stress, appears more amenable to regression than replacement scarring. Treating the underlying cause, whether it is uncontrolled blood pressure, unmanaged diabetes, or persistent inflammation, and applying anti-fibrotic medications can stabilize or improve the collagen balance. The blood markers used to track fibrosis activity, including collagen synthesis and degradation fragments, can shift in favorable directions within months of starting appropriate therapy, as seen with spironolactone in at-risk patients.28European Heart Journal. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial The practical takeaway is that early detection and intervention matter enormously. The earlier fibrosis is caught, the more likely it is to be slowed, stabilized, or partially reversed rather than progressing to a point where the heart cannot recover.
Radiation-Induced Fibrosis as a Special Case
Fibrosis caused by chest radiation deserves separate mention because its timeline and detection differ from the more common causes. Radiation damages the small blood vessels of the heart and triggers a slow inflammatory and fibrotic response that may take months to years to become clinically apparent. In one cardiac MRI study of patients who had undergone radiotherapy, areas of scar were detected within about a year of treatment, but the presence of scar did not clearly correlate with how high the radiation dose to the heart had been.39PubMed Central. Cardiac MRI utilizing late gadolinium enhancement (LGE) and T1 mapping in the detection of radiation induced heart disease This unpredictability makes screening important for cancer survivors who received chest radiation, even if their treatment was years ago and even if they feel fine. Modern radiation techniques aim to minimize heart exposure, but the risk has not been eliminated, and long-term cardiac monitoring after chest radiotherapy is increasingly recommended.